Glenmark Pharmaceuticals Ltd (NSE:GLENMARK)
₹ 1194.15 -15.7 (-1.3%) Market Cap: 336.71 Bil Enterprise Value: 330.69 Bil PE Ratio: 0 PB Ratio: 4.29 GF Score: 83/100

Q3 2020 Glenmark Pharmaceuticals Ltd Earnings Call Transcript

Feb 17, 2020 / 03:00AM GMT
Release Date Price: ₹310.4 (-7.01%)
Operator

Ladies and gentlemen, good day and welcome to the Q3 FY '20 Earning Conference Call of Glenmark Pharmaceuticals Limited.

(Operator Instructions) Please note that this conference is being recorded.

I would now like to hand the conference over to Mr. Jason D'souza. Thank you. And over to you, sir.

Jason D;souza
Glenmark Pharmaceuticals Limited - Senior VP & Head of Corporate Strategy

' -

Thank you, moderator. Welcome to Glenmark's Q3 Earnings Call.

First, a review of operations for the quarter ended December 31, 2019.

For the third quarter of FY '19/'20, Glenmark's consolidated revenue was INR 27,355 million, as against INR 25,500 million, recording an increase of 7.07%. For the 9 months ended December 31, 2019, Glenmark's consolidated revenue was at INR 78,734 million, recording an increase of 7.83%.

India business. Sales from the formulation business in India for the third quarter was at 7,888.39 million, as against INR 6,675 million, recording a growth of 18.17%.

The India business

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot